Cidara Therapeutics, Inc. CDTX 深 沪
等待开盘 11-12 09:30:00 美东时间
221.38
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 221.38
- 总市值 69.74亿
- 52周最高 221.42
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 15.22
- 委 比 0.00%
- 总股本 3150.43万
- 历史最高 382.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.00
- 每 手 1
- 风险率 37.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Merck Q3 2026 Earnings: Sales Rise 5% as EPS Declines
Merck’s Q3 2026 revenue rose 5% to $18.09 billion, led by KEYTRUDA, WINREVAIR, GARDASIL and Animal Health, while GAAP EPS fell 12% to $2.04 and non-GAAP EPS declined 3% to $2.49. GAAP gross margin narrowed to 72.9% as higher R&D, launch spending, intangible amortization, restructuring and net interest expense outweighed sales growth. Merck narrowed its full-year sales outlook to $66.8 billion-$67.3 billion and raised its non-GAAP EPS range to $2.
10-29 10:43
Merck Stock Jumps on Phase 3 Cancer Vaccine Win as Keytruda Risk Eases
TradingKey - Merck stock surged after its personalized mRNA cancer therapy met both Phase 3 melanoma endpoints. Strong Q2 sales and pipeline growth support MRK’s outlook.
08-20 02:27
Kazia Therapeutics Appoints James Levine As CFO, Effective June 1
Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies."James has built an impressive career leading financial strategy,
06-02 19:39
Strong biopharma dealmaking market set to continue
The strong trend in pharma and biotech dealmaking, which has been ongoing for several years, should continue according to experts. Speaking at the FT US Pharma and Biotech Summit in New York, Eric Tok...
05-15 01:41
Merck Swings To Quarterly Loss On Cidara Deal
Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.
05-01 01:10
